Cerity Partners LLC Purchases 4,165 Shares of DaVita Inc. (NYSE:DVA)

Cerity Partners LLC increased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 26.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,644 shares of the company's stock after acquiring an additional 4,165 shares during the quarter. Cerity Partners LLC's holdings in DaVita were worth $3,220,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Transcendent Capital Group LLC acquired a new stake in DaVita during the 3rd quarter worth $25,000. Blue Trust Inc. increased its holdings in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. acquired a new position in DaVita in the second quarter valued at about $43,000. Versant Capital Management Inc boosted its holdings in DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after buying an additional 155 shares during the last quarter. Finally, Friedenthal Financial bought a new position in DaVita during the second quarter worth about $48,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Up 0.3 %

Shares of DaVita stock traded up $0.54 on Friday, hitting $166.17. The company had a trading volume of 314,276 shares, compared to its average volume of 828,300. DaVita Inc. has a twelve month low of $99.18 and a twelve month high of $169.51. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a 50-day moving average of $158.57 and a 200-day moving average of $149.39. The firm has a market capitalization of $13.63 billion, a P/E ratio of 17.93, a P/E/G ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.85 earnings per share. Research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Bank of America increased their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a report on Monday, October 7th. Finally, Barclays upped their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $161.80.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 2.00% of the stock is owned by corporate insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.